Please assess the completion status of the following clinical trial:

Trial Title: Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pacemaker, defibrillator or insertable cardiac monitor implanted for any reason with feature of detection of AHRE, implanted at least 2 months prior to randomisation~* AHRE detection feature activated for adequate detection of AHRE (refer to Appendix XIII)~* AHRE (≥ 170 bpm atrial rate and ≥ 6 min duration) documented by the implanted device via its atrial lead and stored digitally. Any AHRE episode recorded is potentially eligible, but AHRE episodes detected in the first 2 months after implantation of a new device involving placement or repositioning of atrial electrodes are not eligible. AHRE episodes recorded in the first two months after a simple box change operation, i.e. exchange of a pacemaker or defibrillator device without exchange or repositioning of atrial electrodes, are eligible~* Provision of signed informed consent~* Age ≥ 65 years~In addition, at least one of the following cardiovascular conditions leading to a modified CHA2DS2VASc score of 2 or more:~* Age ≥ 75 years~* Heart failure (clinically overt or LVEF \< 45%)~* Arterial hypertension (chronic treatment for hypertension, estimated need for continuous antihyper-tensive therapy or resting blood pressure \> 145/90 mmHg)~* Diabetes mellitus~* Prior stroke or transient ischemic attack (TIA)~* Vascular disease (previous myocardial infarction, peripheral, carotid/cerebral, or aortic plaques on transesophageal echocardiogram \[TEE\])~* Provision of signed informed consent~Exclusion Criteria:~* Any disease that limits life expectancy to less than 1 year~* Participation in another controlled clinical trial, either within the past two months or still ongoing~* Previous participation in the present trial NOAH - AFNET 6~* Drug abuse or clinically manifest alcohol abuse~* Any history of overt AF or atrial flutter~* Indication for oral anticoagulation (e.g. deep venous thrombosis)~* Contraindication for oral anticoagulation in general~* Contraindication for edoxaban as stated in the current SmPC~* Indication for long-term antiplatelet therapy other than acetylsalicylic acid or a need for treatment with any antiplatelet agent in addition to edoxaban, especially dual antiplatelet therapy (DAPT). Patients with a transient requirement for DAPT (e.g. after receiving a stent) will be eligible when the need for DAPT is no longer present~* Acute coronary syndrome, coronary revascularisation (PCI or bypass surgery), or overt stroke within 30 days prior to randomisation~* End stage renal disease (creatinine clearance (CrCl) \< 15 ml/min as calculated by the Cockcroft-Gault method)~* All persons exempt from participation in a clinical trial by law

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Edoxaban (Type: EXPERIMENTAL): Edoxaban will be applied in NOAH at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics:~Impaired renal function (CrCl 15-50 ml/min), or low body weight (≤60 kg), or patients receiving the glycoprotein-P inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole.
- ASA or Placebo (Type: ACTIVE_COMPARATOR): Either one tablet of ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg or one placebo tablet matching in colour, weight, form and size to ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg will be administered per day depending on the indication for use of antiplatelet therapy as assessed by the responsible investigator

Based on this trial design, predict the completion outcome and termination type (if applicable).